Navigation Links
Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
Date:9/9/2008

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Epiphany Biosciences, Inc. today announced that a Phase 2b dose-ranging study to evaluate the safety, efficacy, and tolerability of the company's lead compound, valomaciclovir (EPB-348) in patients with acute herpes zoster infection (shingles), will continue as originally designed following an interim analysis.

Fred Volinsky, MD, Epiphany's CEO said, "We are pleased with the progress of this clinical trial and look forward to the final data. If successful, valomaciclovir will mark an advance in the treatment of herpes zoster which affects more than two million people annually around the globe. As the world population ages, it is expected that the incidence of this disease will grow significantly, especially in lieu of the lackluster response to vaccines in this area. We look to valomaciclovir to enhance the treatment experience by being the first once-daily therapy for shingles." The Phase 2b study is being conducted at sites throughout North America and uses an active comparator, valacyclovir. Outcomes assessed include various efficacy parameters including time to vesicular resolution and safety data collection.

In addition to the Phase 2b zoster study, valomaciclovir will also be studied in a separate Phase 2 clinical trial as a therapy in managing the most severe sequelae of a herpes-zoster infection, post-herpetic neuralgia or PHN. "The spectrum of disease caused by herpes viruses is underappreciated but a disease like shingles can have a profound impact on the quality-of-life of patients, many times leading to severe pain syndromes that could have a viral etiology. We look forward to examining the clinical utility of valomaciclovir in multiple conditions associated with herpes viruses and plan to maximize the broad-acting antiviral profile of this drug," reported Brian Murphy, MD, Chief Medical Officer of Epiphany.

In addition to the studies directed at herpes zoster, valomaciclovir is also being studied in a Phase 2 trial of acute infectious mononucleosis, a syndrome commonly seen in adolescents and young adults, caused by Epstein-Barr virus (EBV), also a member of the herpes virus family. "Further studies of valomaciclovir outside herpes zoster are warranted and we plan to examine uses of this drug in major diseases associated with EBV," commented Dr. Murphy.

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr virus (EBV) and hepatitis C virus (HCV).

Fred Volinsky, CEO

415 765 7193


'/>"/>
SOURCE Epiphany Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing ... the results of a simple test will take days to arrive to the end ... offers customers direct access to their lab tests, bypassing the cost and delay of ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Seamild, the ... on the futuristic vision of its owner and founder. As Oat is recognized globally ... to everybody he knows personally as he believes it is a move to sow ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... its new medical office in Petaluma, located at 167 Lynch Creek Way. The ... to SRO sports medicine and rehabilitation services and on-site x-ray services. ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Bionic Sports ... all walks of life, announced it had a successful January ECRM Trade Show in ... in the United States, which allows it to provide its products to all clients ...
Breaking Medicine News(10 mins):